Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03815110 · ClinicalTrials.gov registry record
Preeclampsia Risk Assessment: Evaluation of Cut-offs to Improve Stratification
A clinical trial, sponsored by Cedars-Sinai Medical Center.
- Completed
- Registry status
- 1,050
- Enrollment target
NCT03815110 is a clinical trial that has completed, run by Cedars-Sinai Medical Center. The registered enrollment target is 1,050 participants.
The verdict
NCT03815110 has completed, sponsored by Cedars-Sinai Medical Center.
- COMPLETED
- Registry status
- 1,050 participants
- Enrollment target
Study Summary
The purpose of this study is to 1. Identify a cut-off for the ratio of the serum proteins soluble FMS-like Tyrosine Kinase 1 (sFLT-1) and placental growth factor (PlGF) that identifies women will who develop preeclampsia with severe features within 2 weeks of testing (clinically positive) from those who do not develop preeclampsia with severe features within 2 weeks of testing (clinically negative) among preterm pregnant women with hypertensive disorders of pregnancy. And 2. To validate the cut-off the ratio of sFLT-1 and PlGF and to validate the performance of the automated assays used to find the cut-off. Test performance includes positive predictive value, negative predictive value, sensitivity, and specificity. Subjects will provide blood, urine, and saliva samples at the time of enrollment. Samples will be frozen for batch assessment of sFLT-1 and PlGF levels by automated assays. Clinicians, subjects, and researchers will be blinded to protein level assessment, therefore assay results will not affect clinical management.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,050 participants |
| Start Date | 2018-12-20 |
| Est. Completion | 2022-10-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03815110
The ClinicalTrials.gov registry entry for NCT03815110 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,050 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cedars-Sinai Medical Center, which has 339 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT03815110 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03815110 about?
NCT03815110 is a clinical study titled "Preeclampsia Risk Assessment: Evaluation of Cut-offs to Improve Stratification". The purpose of this study is to 1. Identify a cut-off for the ratio of the serum proteins soluble FMS-like Tyrosine Kinase 1 (sFLT-1) and placental growth factor (PlGF) that identifies women will who develop preeclampsia with severe features within 2 weeks of testing (clinically positive) from thos...
What is the current status of trial NCT03815110?
This trial is currently completed. The enrollment target is 1,050 participants. The study started on 2018-12-20. Estimated completion is 2022-10-01.
Who is sponsoring clinical trial NCT03815110?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.